
AstraZeneca Acquires Omniose for Vaccine Pipeline
AstraZeneca has acquired early-stage biotechnology firm Omniose to bolster its infectious diseases division. The deal integrates a proprietary bioconjugation platform to advance new bacterial vaccines.
Xurve View
Insights:
Xurve View

ASTRAZENECA PLC acquired early-stage biotechnology firm Omniose on Tuesday to bolster its vaccine pipeline against serious bacterial infections. Financial terms of the undisclosed transaction remain confidential between the parties. The buyout follows a three-year exclusive research collaboration between the two drug developers.










